Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Liabilities and Shareholders Equity (2021 - 2024)

Opus Genetics (IRD) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $54.2 million as the latest value for Q3 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 271.99% to $54.2 million in Q3 2023 year-over-year; TTM through Dec 2023 was $143.1 million, a 40.33% increase, with the full-year FY2022 number at $49.0 million, up 87.87% from a year prior.
  • Liabilities and Shareholders Equity was $54.2 million for Q3 2023 at Opus Genetics, up from $43.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $54.2 million in Q3 2023 to a low of $12.1 million in Q1 2021.
  • A 3-year average of $30.2 million and a median of $25.3 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 37.22% in 2022, then surged 271.99% in 2023.
  • Opus Genetics' Liabilities and Shareholders Equity stood at $26.1 million in 2021, then skyrocketed by 87.87% to $49.0 million in 2022, then rose by 10.61% to $54.2 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Liabilities and Shareholders Equity are $54.2 million (Q3 2023), $43.5 million (Q2 2023), and $45.4 million (Q1 2023).